Companies · CE
Celanese
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 5, 2026
Celanese Q2 2026 earnings call: Acetyl Chain supply dislocation benefits moderate as expected; EM mix enrichment and drug delivery growth emerge as structural earnings levers.
Celanese demonstrated operational agility in Q2 2026 by capitalizing on Middle East supply disruptions through rapid reactivation of the Frankfurt plant and Western Hemisphere capacity flex, driving Acetyl Chain profitability above initial guidance before an anticipated H2 normalization. In Engineered Materials, management exited Q2 with strong pricing momentum sufficient to partially offset raw material inflation in Q3, while electronics and medical subsegments — representing 10-15% and roughly 20% of EM contribution margin respectively — are being repositioned as structural growth platforms. The company reaffirmed $700-800 million free cash flow guidance for 2026 and framing it explicitly as a 'baseline sustainable level,' targeting net debt of approximately $9 billion by end-2027 on a path to 3x long-term leverage.
Tone: mixedRevenue
$9.5B
CE 10-K · FY 2025
Employees
11,434
Revenue FY2024
$10.3B
Founded
1918
Profile
CE 10-K Item 1 · Feb 24, 2026Celanese is a global chemical and specialty materials company with two principal segments: Engineered Materials and the Acetyl Chain. The company produces high-performance engineered polymers and is one of the world's largest producers of acetyl intermediates, serving end markets from automotive and medical to construction and consumer electronics. Its 51 global production facilities and 20 strategic affiliate sites give it geographically balanced exposure across North America, Europe and Asia.
Read filing description ↓ Collapse description ↑
We are a global chemical and specialty materials company. We are a global producer of high performance engineered polymers that are used in a variety of high-value applications, as well as one of the world's largest producers of acetyl products, which are intermediate chemicals for nearly all major industries. As a recognized innovator in the chemicals industry, we engineer and manufacture a wide variety of products essential to everyday living. Our broad product portfolio serves a diverse set of end-use applications including automotive, chemical additives, construction, consumer and industrial adhesives, medical, consumer electronics, energy storage, filtration, paints and coatings, paper and packaging, industrial applications and textiles. Our products enjoy leading global positions due to our differentiated business models, large global production capacity, operating efficiencies, proprietary technology and competitive cost structures. Our large and diverse global customer base primarily consists of major companies across a broad array of industries. We hold geographically balanced global positions and participate in diversified end-use applications. We combine a demonstrated track record of execution, strong performance built on differentiated business models and a clear focus on growth and value creation. Known for operational excellence, reliability and execution of our business strategies, we partner with our customers around the globe to deliver best-in-class technologies and solutions. Headquartered in Irving, Texas, our operations are primarily located in North America, Europe and Asia and consist of 51 global production facilities and an additional 20 strategic affiliate production facilities.
Primary products
- Ethylene acrylic elastomers (EAE)
- Ethylene vinyl acetate (EVA) pharmaceutical grade copolymers
- Liquid crystal polymers (LCP)
- Long-fiber reinforced thermoplastics (LFRT)
- Nylon compounds or formulations
- Polyoxymethylene (POM)
Business segments
End markets
Geographies
Named customers
Acetate tow is sold principally to the major tobacco companies that account for a majority of worldwide cigarette production.
“We believe our production technology is among the lowest cost in the industry and provides us with global growth opportunities through low cost expansions and a cost advantage over our competitors.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Net sales decreased $724 million, or 7%, for the year ended December 31, 2025 compared to 2024, driven by lower volume in both segments amid weaker global economic conditions and lower Acetyl Chain pricing, partially offset by a favorable currency impact from a stronger euro.
The rest of CE is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.